Advances in Targets for CAR T Therapy in Hematologic Malignancies

Dear Colleagues,

Chimeric Antigen Receptor T-cell (CAR T) therapy has revolutionized the treatment landscape for hematologic malignancies, offering unprecedented outcomes for patients with otherwise refractory or relapsed diseases. By genetically engineering T cells to express synthetic receptors targeting tumor-associated antigens, CAR T therapy has demonstrated remarkable efficacy, particularly in B-cell malignancies such as acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). However, the success of CAR T therapy hinges on the identification of optimal targets that ensure robust anti-tumor activity while minimizing off-tumor toxicities.

Recent advances in target discovery and design have expanded the repertoire of antigens, including innovative approaches such as dual-targeting CARs, logic-gated designs, and targets associated with the tumor microenvironment. These strategies aim to overcome challenges like antigen escape, heterogeneity, and immune-related adverse effects. This Special Issue makes the point on current achievements and explores emerging targets for CAR T therapy in hematologic malignancies, highlighting their potential to improve therapeutic efficacy and safety while paving the way for broader applicability in clinical settings.

Dr. Ugo Testa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.